Gan & Lee Pharmaceuticals Begins GRADUAL-3 Study for Weight Management
Gan & Lee Pharmaceuticals has recently taken an exciting step toward advancing weight management therapies. The company is launching its third pivotal phase 3 clinical study, called GRADUAL-3, focusing on the glucagon-like peptide-1 receptor agonist (GLP-1 RA) known as bofanglutide (research code: GZR18). This study is particularly noteworthy as it marks the first instance of a once-monthly GLP-1 RA being developed in China specifically for weight management purposes.
Study Details and Goals
The GRADUAL-3 clinical trial aims to assess the effectiveness and safety of administering bofanglutide injection once a month for adults managing obesity or who are overweight. Participants in this study will receive the treatment subcutaneously every four weeks, focusing on maintaining weight loss achieved during the study period and ensuring long-term adherence to the treatment regimen.
Under the guidance of distinguished principal investigator Professor Linong Ji from Peking University People’s Hospital, the study will observe changes in body weight over a 24-week continuous treatment phase. The trials seek to understand both the absolute change in body weight and the percentage change from baseline measures at the 24-week marker.
Previous Studies and Efficacy
Gan & Lee's commitment to developing effective weight management solutions can be traced back to earlier studies: GRADUAL-1 and GRADUAL-2. In the GRADUAL-2 trial, bofanglutide was evaluated in a head-to-head study against semaglutide, also known as Wegovy, which is widely recognized for its role in weight loss. This aspect highlights the competitive positioning of bofanglutide in the global market, as it undergoes rigorous evaluation for use in treating obesity both with and without type 2 diabetes.
The GRADUAL-3 trial builds on the knowledge gained from previous trials, aiming to document the sustained weight loss benefits and overall impact on metabolic health of participants. Weight regain after initial loss is a common challenge in weight management. Therefore, by exploring the benefits of a once-monthly dosage, this trial hopes to enhance treatment adherence and mitigate risks associated with weight regain over time.
Understanding the GRADUAL Clinical Development Program
The GRADUAL clinical development program encompasses a comprehensive assessment of bofanglutide injection's safety and efficacy for individuals struggling with obesity or overweight. Notably, three large-scale phase 3 clinical studies are being conducted concurrently in China, targeting over 1,000 participants to contribute to the growing body of evidence supporting the treatment’s potential benefits.
Highlights from GRADUAL Clinical Trials
- GRADUAL-1: This 52-week study recruited approximately 630 adults, measuring the efficacy and safety of bofanglutide for those who have not seen significant weight loss through diet and exercise alone.
- GRADUAL-2: Another 52-week study involving about 471 participants aimed to compare the effects of bofanglutide to semaglutide, allowing insights into their respective safety and efficacy.
- GRADUAL-3: The current phase 3 study looks to evaluate the long-term effects of the once-monthly administration on weight maintenance and overall participant health.
The Promise of Bofanglutide Injection
Bofanglutide, developed by Gan & Lee Pharmaceuticals, represents a novel approach within the GLP-1 RA category. The focus extends beyond treating obesity to include potential applications for type 2 diabetes as well. Clinical trials have demonstrated its remarkable effects in promoting weight loss and reducing glucose levels while improving metabolic health measures. Importantly, the safety profile of bofanglutide aligns with existing GLP-1 RA therapies, indicating a strong potential for integration into broader therapeutic options.
Frequently Asked Questions
What is the goal of the GRADUAL-3 study?
The GRADUAL-3 study aims to evaluate the efficacy and safety of once-monthly bofanglutide injection in maintaining weight loss and improving treatment adherence.
Who is leading the GRADUAL-3 clinical trial?
Professor Linong Ji from Peking University People’s Hospital is the principal investigator overseeing the GRADUAL-3 study.
How many participants are involved in the GRADUAL clinical development program?
Over 1,000 participants are planned to be enrolled across the three ongoing phase 3 studies within the GRADUAL program.
What distinguishes bofanglutide from other GLP-1 RAs?
Bofanglutide is notable for being a once-monthly injection developed specifically for weight management, aimed at improving long-term treatment adherence.
What were the previous studies before GRADUAL-3?
The previous studies, GRADUAL-1 and GRADUAL-2, assessed bofanglutide's efficacy and safety compared to other treatments, including semaglutide.
